{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T00:59:43Z","timestamp":1792285183300,"version":"4.4.0"},"reference-count":103,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T00:00:00Z","timestamp":1572825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003246","name":"Netherlands Organisation for Scientific Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["ERC-2011-AdG-290836"],"award-info":[{"award-number":["ERC-2011-AdG-290836"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Chemical Biology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.cbpa.2019.10.006","type":"journal-article","created":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T23:08:43Z","timestamp":1574723323000},"page":"204-215","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":74,"special_numbering":"C","title":["Glycosphingolipids and lysosomal storage disorders as illustrated by gaucher disease"],"prefix":"10.1016","volume":"53","author":[{"given":"Johannes M.F.G.","family":"Aerts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Lin","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey T.","family":"Lelieveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphne E.C.","family":"Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn J.C.","family":"van der Lienden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herman S.","family":"Overkleeft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Artola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cbpa.2019.10.006_bib1","series-title":"A\u00a0treatise on the chemical constitution of the brain","author":"Thudichum","year":"1884"},{"key":"10.1016\/j.cbpa.2019.10.006_bib2","doi-asserted-by":"crossref","first-page":"6387","DOI":"10.1021\/cr2002917","article-title":"Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics","volume":"111","author":"Merrill","year":"2011","journal-title":"Chem Rev"},{"key":"10.1016\/j.cbpa.2019.10.006_bib3","doi-asserted-by":"crossref","first-page":"8848","DOI":"10.1002\/anie.200902620","article-title":"Glycosphingolipids-nature, function, and pharmacological modulation","volume":"48","author":"Wennekes","year":"2009","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.cbpa.2019.10.006_bib4","series-title":"Essentials of glycobiology","year":"2017"},{"key":"10.1016\/j.cbpa.2019.10.006_bib5","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1007\/s11064-012-0734-0","article-title":"The hypothesis on function of glycosphingolipids and ABO blood groups revisited","volume":"37","author":"Ko\u015bcielak","year":"2009","journal-title":"Neurochem Res"},{"key":"10.1016\/j.cbpa.2019.10.006_bib6","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1002\/jnr.21992","article-title":"Myelin-associated glycoprotein and its axonal receptors","volume":"87","author":"Schnaar","year":"2009","journal-title":"J\u00a0Neurosci Res"},{"key":"10.1016\/j.cbpa.2019.10.006_bib7","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1182\/blood-2008-04-149641","article-title":"E-selectin receptors on human leukocytes","volume":"112","author":"Nimrichter","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.cbpa.2019.10.006_bib8","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0966-842X(96)10017-2","article-title":"Role of verotoxin receptors in pathogenesis","volume":"4","author":"Lingwood","year":"1996","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.cbpa.2019.10.006_bib9","first-page":"303","article-title":"The role of glycosphingolipids in HIV\/AIDS","volume":"11","author":"Lingwood","year":"2011","journal-title":"Discov Med"},{"key":"10.1016\/j.cbpa.2019.10.006_bib10","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1002\/1873-3468.13275","article-title":"The regulatory roles of glycosphingolipid-enriched lipid rafts in immune systems","volume":"592","author":"Nakayama","year":"2008","journal-title":"FEBS Lett"},{"key":"10.1016\/j.cbpa.2019.10.006_bib11","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1182\/blood-2014-09-600270","article-title":"Type II NKT-TFH cells against Gaucher lipids regulate B-cell immunity and inflammation","volume":"125","author":"Nair","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.cbpa.2019.10.006_bib12","first-page":"4","article-title":"Membrane domains and the \"lipid raft\" concept","volume":"20","author":"Sonnino","year":"2013","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.cbpa.2019.10.006_bib13","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1126\/science.1174621","article-title":"Lipid rafts as a membrane-organizing principle","volume":"327","author":"Lingwood","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.cbpa.2019.10.006_bib14","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1074\/jbc.M103705200","article-title":"Ganglioside GM3 participates in the pathological conditions of insulin resistance","volume":"277","author":"Tagami","year":"2002","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.cbpa.2019.10.006_bib15","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.2337\/db06-1619","article-title":"Pharmacological inhibition of GC synthase enhances insulin sensitivity","volume":"56","author":"Aerts","year":"2007","journal-title":"Diabetes"},{"key":"10.1016\/j.cbpa.2019.10.006_bib16","doi-asserted-by":"crossref","first-page":"13678","DOI":"10.1073\/pnas.0703650104","article-title":"Dissociation of the insulin receptor and caveolin-1 complex by ganglioside GM3 in the state of insulin resistance","volume":"104","author":"Kabayama","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cbpa.2019.10.006_bib17","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1073\/pnas.0635898100","article-title":"Enhanced insulin sensitivity in mice lacking ganglioside GM3","volume":"100","author":"Yamashita","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cbpa.2019.10.006_bib18","doi-asserted-by":"crossref","first-page":"27896","DOI":"10.1074\/jbc.M212200200","article-title":"Overexpression of plasma membrane-associated sialidase attenuates insulin signaling in transgenic mice","volume":"278","author":"Sasaki","year":"2003","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.cbpa.2019.10.006_bib19","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/bs.pmbts.2017.10.004","article-title":"Biology of GM3 ganglioside","volume":"156","author":"Inokuchi","year":"2018","journal-title":"Prog Mol Biol Transl Sci"},{"key":"10.1016\/j.cbpa.2019.10.006_bib20","doi-asserted-by":"crossref","first-page":"4638","DOI":"10.1073\/pnas.93.10.4638","article-title":"Expression cloning of a cDNA for human ceramide glucosyltransferase that catalyzes the first glycosylation step of glycosphingolipid synthesis","volume":"93","author":"Ichikawa","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cbpa.2019.10.006_bib21","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0925-4439(93)90090-N","article-title":"Demonstration of the existence of a second, non-lysosomal glucocerebrosidase that is not deficient in Gaucher disease","volume":"1181","author":"van Weely","year":"1993","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.cbpa.2019.10.006_bib22","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.febslet.2009.10.021","article-title":"Lysosomal degradation of membrane lipids","volume":"584","author":"Kolter","year":"2010","journal-title":"FEBS Lett"},{"key":"10.1016\/j.cbpa.2019.10.006_bib23","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nature13476","article-title":"Sphingolipid lysosomal storage disorders","volume":"510","author":"Platt","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.cbpa.2019.10.006_bib24","doi-asserted-by":"crossref","first-page":"10195","DOI":"10.1523\/JNEUROSCI.0822-13.2013","article-title":"Gangliosides and gangliosidoses: principles of molecular and metabolic pathogenesis","volume":"33","author":"Sandhoff","year":"2013","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.cbpa.2019.10.006_bib25","series-title":"De l'epithelioma primitif de la rate, hypertrophie idiopathique de la rate sans leucemie","author":"Gaucher","year":"1882"},{"key":"10.1016\/j.cbpa.2019.10.006_bib26","series-title":"The metabolic and molecular bases of inherited diseases","article-title":"Glucosylceramide lipidosis-gaucher disease","author":"Beutler","year":"2001"},{"key":"10.1016\/j.cbpa.2019.10.006_bib27","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1172\/JCI105417","article-title":"Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher's disease","volume":"45","author":"Brady","year":"1966","journal-title":"J\u00a0Clin Investig"},{"key":"10.1016\/j.cbpa.2019.10.006_bib28","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.bbalip.2013.11.004","article-title":"Gaucher disease and Fabry disease: new markers and insights in pathophysiology for two distinct glycosphingolipidoses","volume":"1841","author":"Ferraz","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.cbpa.2019.10.006_bib29","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1194\/jlr.M079376","article-title":"In situ visualization of glucocerebrosidase in human skin tissue: zymography versus activity-based probe labeling","volume":"58","author":"Van Smeden","year":"2017","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.cbpa.2019.10.006_sref30","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1093\/brain\/awu002","article-title":"Glucocerebrosidase is shaking up the synucleinopathies","volume":"137","author":"Siebert","year":"2014","journal-title":"Brain"},{"key":"10.1016\/j.cbpa.2019.10.006_bib31","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/ajh.23118","article-title":"Genome-wide association study of N370S homozygous Gaucher disease reveals the candidacy of CLN8 gene as a genetic modifier contributing to extreme phenotypic variation","volume":"87","author":"Zhang","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.cbpa.2019.10.006_bib32","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/s41556-018-0228-7","article-title":"CLN8 is an endoplasmic reticulum cargo receptor that regulates lysosome biogenesis","volume":"20","author":"di Ronza","year":"2018","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.cbpa.2019.10.006_bib33","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.ymgme.2011.09.010","article-title":"Gaucher disease due to saposin C deficiency, previously described as non-neuronopathic form--no positive effects after 2-years of miglustat therapy","volume":"104","author":"Tylki-Szyma\u0144ska","year":"2011","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.cbpa.2019.10.006_bib34","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0304-4165(88)90030-X","article-title":"Glucocerebrosidase, a lysosomal enzyme that does not undergo oligosaccharide phosphorylation","volume":"964","author":"Aerts","year":"1988","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.cbpa.2019.10.006_bib35","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.cell.2007.10.018","article-title":"LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase","volume":"131","author":"Reczek","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.cbpa.2019.10.006_bib36","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1002\/humu.21566","article-title":"A\u00a0mutation in SCARB2 is a modifier in Gaucher disease","volume":"32","author":"Velayati","year":"2011","journal-title":"Hum Mutat"},{"key":"10.1016\/j.cbpa.2019.10.006_bib37","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1002\/humu.22381","article-title":"Characterization of variants in the glucosylceramide synthase gene and their association with type 1 Gaucher disease severity","volume":"34","author":"Alfonso","year":"2013","journal-title":"Hum Mutat"},{"key":"10.1016\/j.cbpa.2019.10.006_bib38","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1080\/15476286.2014.996085","article-title":"Identification of miRNAs that modulate glucocerebrosidase activity in Gaucher disease cells","volume":"11","author":"Siebert","year":"2014","journal-title":"RNA Biol"},{"key":"10.1016\/j.cbpa.2019.10.006_bib39","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1309\/BG5VA8JRDQH1M7HN","article-title":"Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages","volume":"122","author":"Boven","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.cbpa.2019.10.006_bib40","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1074\/mcp.M600303-MCP200","article-title":"Analysis and quantification of diagnostic markers and protein signatures for Gaucher disease by means of LC-MS","volume":"6","author":"Vissers","year":"2007","journal-title":"Mol Cell Proteom"},{"key":"10.1016\/j.cbpa.2019.10.006_bib41","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1046\/j.1365-2141.1997.d01-2076.x","article-title":"Coagulation abnormalities in type 1 Gaucher disease are due to low-grade activation and can be partly restored by enzyme supplementation therapy","volume":"96","author":"Hollak","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cbpa.2019.10.006_bib42","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1172\/JCI117084","article-title":"Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease","volume":"93","author":"Hollak","year":"1994","journal-title":"J\u00a0Clin Investig"},{"key":"10.1016\/j.cbpa.2019.10.006_bib43","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0074-7696(06)52001-7","article-title":"The biology of the Gaucher cell: the cradle of human chitinases","volume":"252","author":"Bussink","year":"2006","journal-title":"Int Rev Cytol"},{"key":"10.1016\/j.cbpa.2019.10.006_bib44","doi-asserted-by":"crossref","first-page":"40911","DOI":"10.1074\/jbc.M301804200","article-title":"Transglycosidase activity of chitotriosidase: improved enzymatic assay for the human macrophage chitinase","volume":"278","author":"Aguilera","year":"2003","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.cbpa.2019.10.006_bib45","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1182\/blood-2003-05-1612","article-title":"Marked elevation of the chemokine CCL18\/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention","volume":"103","author":"Boot","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.cbpa.2019.10.006_bib46","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/2211-5463.12078","article-title":"Elevation of glycoprotein nonmetastatic melanoma protein B in type 1 Gaucher disease patients and mouse models","volume":"30","author":"Kramer","year":"2016","journal-title":"FEBS Open Bio"},{"key":"10.1016\/j.cbpa.2019.10.006_bib47","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bcmd.2016.12.002","article-title":"Validating glycoprotein non-metastatic melanoma B (gpNMB, osteoactivin), a new biomarker of Gaucher disease","volume":"68","author":"Murugesan","year":"2018","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.cbpa.2019.10.006_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120194","article-title":"Identification of a biomarker in cerebrospinal fluid for neuronopathic forms of Gaucher disease","volume":"10","author":"Zigdon","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.cbpa.2019.10.006_bib49","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.cca.2007.12.001","article-title":"Prominent increase in plasma ganglioside GM3 is associated with clinical manifestations of type I Gaucher disease","volume":"389","author":"Ghauharali-van der Vlugt","year":"2008","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.cbpa.2019.10.006_bib50","doi-asserted-by":"crossref","first-page":"196205","DOI":"10.1016\/j.plipres.2009.03.002","article-title":"Glycosphingolipids and insulin resistance","volume":"48","author":"Langeveld","year":"2009","journal-title":"Prog Lipid Res"},{"key":"10.1016\/j.cbpa.2019.10.006_bib51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135889","article-title":"Reducing GBA2 activity ameliorates neuropathology in niemann-pick type C mice","volume":"10","author":"Marques","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.cbpa.2019.10.006_bib52","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.ymgme.2012.01.020","article-title":"Iminosugar-based inhibitors of glucosylceramide synthase prolong survival but paradoxically increase brain glucosylceramide levels in Niemann-Pick C mice","volume":"105","author":"Nietupski","year":"2012","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.cbpa.2019.10.006_bib53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021758","article-title":"Iminosugar-based inhibitors of glucosylceramide synthase increase brain glycosphingolipids and survival in a mouse model of Sandhoff disease","volume":"6","author":"Ashe","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.cbpa.2019.10.006_bib54","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1194\/jlr.M064923","article-title":"Glucosylated cholesterol in mammalian cells and tissues: formation and degradation by multiple cellular \u03b2-glucosidases","volume":"57","author":"Marques","year":"2016","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.cbpa.2019.10.006_sref55","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/1873-3468.12104","article-title":"Lysosomal glycosphingolipid catabolism by acid ceramidase: formation of glycosphingoid bases during deficiency of glycosidases","volume":"590","author":"Ferraz","year":"2016","journal-title":"FEBS Lett"},{"key":"10.1016\/j.cbpa.2019.10.006_bib56","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1373\/clinchem.2006.079012","article-title":"HPLC for simultaneous quantification of total ceramide, glucosylceramide, and ceramide trihexoside concentrations in plasma","volume":"53","author":"Groener","year":"2007","journal-title":"Clin Chem"},{"key":"10.1016\/j.cbpa.2019.10.006_bib57","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1182\/blood-2011-05-352971","article-title":"Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response","volume":"118","author":"Dekker","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.cbpa.2019.10.006_bib58","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.bcmd.2015.01.006","article-title":"Mass spectrometric quantification of glucosylsphingosine in plasma and urine of type 1 Gaucher patients using an isotope standard","volume":"54","author":"Mirzaian","year":"2015","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.cbpa.2019.10.006_sref59","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1021\/jacs.9b00056","article-title":"Functionalized cyclophellitols are selective glucocerebrosidase inhibitors and induce a bona fide neuropathic Gaucher model in zebrafish","volume":"141","author":"Artola","year":"2019","journal-title":"J\u00a0Am Chem Soc"},{"key":"10.1016\/j.cbpa.2019.10.006_bib60","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/mt.2015.16","article-title":"Lentiviral gene therapy using cellular promoters cures type 1 Gaucher disease in mice","volume":"23","author":"Dahl","year":"2015","journal-title":"Mol Ther"},{"key":"10.1016\/j.cbpa.2019.10.006_bib61","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1073\/pnas.1400768111","article-title":"Glucocerebrosidase 2 gene deletion rescues type 1 Gaucher disease","volume":"111","author":"Mistry","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cbpa.2019.10.006_sref62","doi-asserted-by":"crossref","first-page":"9617","DOI":"10.1523\/JNEUROSCI.1525-17.2017","article-title":"Glucosylsphingosine promotes \u03b1-synuclein pathology in mutant GBA-associated Parkinson's disease","volume":"37","author":"Taguchi","year":"2017","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.cbpa.2019.10.006_bib63","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa1508808","article-title":"Clonal immunoglobulin against lysolipids in the origin of myeloma","volume":"374","author":"Nair","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cbpa.2019.10.006_bib64","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.smim.2018.02.006","article-title":"An unexpected player in Gaucher disease: the multiple roles of complement in disease development","volume":"37","author":"Pandey","year":"2018","journal-title":"Semin Immunol"},{"key":"10.1016\/j.cbpa.2019.10.006_bib65","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/path.4992","article-title":"Reduced cerebral vascularization in experimental neuronopathic Gaucher disease","volume":"244","author":"Smith","year":"2018","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.cbpa.2019.10.006_bib66","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1098\/rstb.2003.1269","article-title":"Enzyme replacement therapy: conception, chaos and culmination","volume":"358","author":"Brady","year":"2003","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.1016\/j.cbpa.2019.10.006_bib67","doi-asserted-by":"crossref","first-page":"961","DOI":"10.2214\/ajr.179.4.1790961","article-title":"Quantification of skeletal involvement in adults with type I Gaucher's disease: fat fraction measured by Dixon quantitative chemical shift imaging as a valid parameter","volume":"179","author":"Maas","year":"2002","journal-title":"Am J Roentgenol"},{"key":"10.1016\/j.cbpa.2019.10.006_bib68","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s10545-006-0272-5","article-title":"Substrate reduction therapy of glycosphingolipid storage disorders","volume":"29","author":"Aerts","year":"2006","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.cbpa.2019.10.006_bib69","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1023\/A:1010335505357","article-title":"Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy","volume":"24","author":"Platt","year":"2001","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.cbpa.2019.10.006_bib70","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.bcmd.2018.04.001","article-title":"Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1","volume":"71","author":"Mistry","year":"2018","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.cbpa.2019.10.006_bib71","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1194\/jlr.R047167","article-title":"The development and use of small molecule inhibitors of glycosphingolipid metabolism for lysosomal storage diseases","volume":"55","author":"Shayman","year":"2014","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.cbpa.2019.10.006_bib72","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s10545-014-9711-x","article-title":"Value of plasma chitotriosidase to assess non-neuronopathic Gaucher disease severity and progression in the era of enzyme replacement therapy","volume":"37","author":"van Dussen","year":"2014","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.cbpa.2019.10.006_bib73","doi-asserted-by":"crossref","first-page":"23502","DOI":"10.1074\/jbc.M109.012393","article-title":"Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease","volume":"284","author":"Maegawa","year":"2009","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.cbpa.2019.10.006_bib74","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.bcmd.2012.09.006","article-title":"Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease","volume":"50","author":"Zimran","year":"2013","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.cbpa.2019.10.006_bib75","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/acn3.292","article-title":"Ambroxol chaperone therapy for neuronopathic Gaucher disease: a pilot study","volume":"3","author":"Narita","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.cbpa.2019.10.006_bib76","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ebiom.2018.11.037","article-title":"The heat shock protein amplifier arimoclomol improves refolding, maturation and lysosomal activity of glucocerebrosidase","volume":"38","author":"Fog","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.cbpa.2019.10.006_sref77","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1021\/ja5106738","article-title":"Fluorescence-quenched substrates for live cell imaging of human glucocerebrosidase activity","volume":"137","author":"Yadav","year":"2015","journal-title":"J\u00a0Am Chem Soc"},{"key":"10.1016\/j.cbpa.2019.10.006_bib78","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/bs.mie.2017.06.014","article-title":"Fluorescence-quenched substrates for quantitative live cell imaging of glucocerebrosidase activity","volume":"598","author":"Ashmus","year":"2018","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.cbpa.2019.10.006_bib79","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1002\/ejoc.201500025","article-title":"Synthesis of a panel of carbon-13-labelled (glyco)sphingolipids","volume":"12","author":"Wisse","year":"2015","journal-title":"Eur J Org Chem"},{"key":"10.1016\/j.cbpa.2019.10.006_sref80","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/nchembio.466","article-title":"Ultrasensitive in situ visualization of active glucocerebrosidase molecules","volume":"6","author":"Witte","year":"2010","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.cbpa.2019.10.006_bib81","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/febs.14744","article-title":"In\u00a0vivo inactivation of glycosidases by conduritol B epoxide and cyclophellitol revealed by activity-based protein profiling","volume":"286","author":"Kuo","year":"2019","journal-title":"FEBS J"},{"key":"10.1016\/j.cbpa.2019.10.006_bib82","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0138107","article-title":"Visualization of active glucocerebrosidase in rodent brain with high spatial resolution following in situ labeling with fluorescent activity based probes","volume":"10","author":"Herrera Moro Chao","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.cbpa.2019.10.006_bib83","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/tra.12641","article-title":"Localization of active endogenous and exogenous GBA by correlative light-electron microscopy in human fibroblasts","volume":"20","author":"van Meel","year":"2019","journal-title":"Traffic"},{"key":"10.1016\/j.cbpa.2019.10.006_bib84","doi-asserted-by":"crossref","first-page":"12529","DOI":"10.1002\/anie.201207771","article-title":"Novel activity-based probes for broad spectrum profiling of retaining \u03b2-exoglucosidases in situ and in\u00a0vivo","volume":"51","author":"Kallemeijn","year":"2012","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.cbpa.2019.10.006_bib85","doi-asserted-by":"crossref","first-page":"35351","DOI":"10.1074\/jbc.M114.593376","article-title":"A\u00a0sensitive gel-based method combining distinct cyclophellitol-based probes for the identification of acid\/base residues in human retaining \u03b2glucosidases","volume":"289","author":"Kallemeijn","year":"2014","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.cbpa.2019.10.006_bib86","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/j.1471-4159.1978.tb12395.x","article-title":"The Gaucher mouse: differential action of conduritol B epoxide and reversibility of its effects","volume":"30","author":"Stephen","year":"1978","journal-title":"J\u00a0Neurochem"},{"key":"10.1016\/j.cbpa.2019.10.006_bib87","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/path.4751","article-title":"Delineating pathological pathways in a chemically induced mouse model of Gaucher disease","volume":"239","author":"Vardi","year":"2016","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.cbpa.2019.10.006_bib88","doi-asserted-by":"crossref","first-page":"14192","DOI":"10.1021\/jacs.7b07352","article-title":"A\u00a0fluorescence Polarization activity-based protein profiling assay in the discovery of potent, selective inhibitors for human Nonlysosomal glucosylceramidase","volume":"139","author":"Lahav","year":"2017","journal-title":"J\u00a0Am Chem Soc"},{"key":"10.1016\/j.cbpa.2019.10.006_bib89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymthe.2019.05.018","article-title":"Substrate reduction therapy for Sandhoff disease through inhibition of glucosylceramide synthase activity","volume":"27","author":"Marshall","year":"2019","journal-title":"Mol Ther"},{"key":"10.1016\/j.cbpa.2019.10.006_bib90","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.cca.2017.01.014","article-title":"Simultaneous quantitation of sphingoid bases by UPLC-ESI-MS\/MS with identical (13)C-encoded internal standards","volume":"466","author":"Mirzaian","year":"2017","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.cbpa.2019.10.006_bib91","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.neulet.2015.01.084","article-title":"The Fabry disease-associated lipid Lyso-Gb3 enhances voltage-gated calcium currents in sensory neurons and causes pain","volume":"594","author":"Choi","year":"2015","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.cbpa.2019.10.006_bib92","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1093\/hmg\/ddv291","article-title":"Lyso-Gb3 activates Notch1 in human podocytes","volume":"24","author":"Sanchez-Ni\u00f1o","year":"2015","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.cbpa.2019.10.006_bib93","doi-asserted-by":"crossref","first-page":"20097","DOI":"10.1073\/pnas.1912108116","article-title":"Genetic ablation of acid ceramidase in Krabbe disease confirms the psychosine hypothesis and identifies a new therapeutic target","volume":"116","author":"Li","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cbpa.2019.10.006_sref94","doi-asserted-by":"crossref","first-page":"10842","DOI":"10.1073\/pnas.1003247107","article-title":"Imaging of enzyme replacement therapy using PET","volume":"107","author":"Phenix","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cbpa.2019.10.006_bib95","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1093\/brain\/awx285","article-title":"Excessive burden of lysosomal storage disorder gene variants in Parkinson's disease","volume":"140","author":"Robak","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.cbpa.2019.10.006_bib96","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00441-017-2704-y","article-title":"Molecular mechanisms of \u03b1-synuclein and GBA1 in Parkinson's disease","volume":"373","author":"Stojkovska","year":"2018","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.cbpa.2019.10.006_bib97","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cell.2011.06.001","article-title":"Gaucher disease glucocerebrosidase and \u03b1-synuclein form a bidirectional pathogenic loop in synucleinopathies","volume":"146","author":"Mazzulli","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.cbpa.2019.10.006_bib98","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/ana.22400","article-title":"Acid beta-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter alpha-synuclein processing","volume":"69","author":"Cullen","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.cbpa.2019.10.006_bib99","article-title":"Drosophila melanogaster mutated in its GBA1b ortholog recapitulates neuronopathic Gaucher disease","volume":"8","author":"Cabasso","year":"2019","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.cbpa.2019.10.006_bib100","doi-asserted-by":"crossref","first-page":"15573","DOI":"10.1073\/pnas.1405700111","article-title":"LIMP-2 expression is critical for \u03b2-glucocerebrosidase activity and \u03b1-synuclein clearance","volume":"111","author":"Rothaug","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cbpa.2019.10.006_bib101","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1093\/hmg\/ddz030","article-title":"GBA haploinsufficiency accelerates alpha-synuclein pathology with altered lipid metabolism in a prodromal model of Parkinson's disease","volume":"28","author":"Ikuno","year":"2019","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.cbpa.2019.10.006_bib102","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1096\/fj.201601299R","article-title":"Neuraminidases 3 and 4 regulate neuronal function by catabolizing brain gangliosides","volume":"31","author":"Pan","year":"2017","journal-title":"FASEB J"},{"key":"10.1016\/j.cbpa.2019.10.006_bib103","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/humu.10268","article-title":"Molecular pathology of NEU1 gene in sialidosis","volume":"22","author":"Seyrantepe","year":"2003","journal-title":"Hum Mutat"}],"container-title":["Current Opinion in Chemical Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1367593119300869?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1367593119300869?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T02:46:40Z","timestamp":1761274000000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1367593119300869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":103,"alternative-id":["S1367593119300869"],"URL":"https:\/\/doi.org\/10.1016\/j.cbpa.2019.10.006","relation":{},"ISSN":["1367-5931"],"issn-type":[{"value":"1367-5931","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glycosphingolipids and lysosomal storage disorders as illustrated by gaucher disease","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Chemical Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbpa.2019.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}